DOCSLIB.ORG

Invasive Aspergillosis Poster IDSA FINAL Pdf.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Invasive Aspergillosis Poster IDSA FINAL Pdf.Pdf Invasive Aspergillosis Associated with Severe Influenza Infections Nancy Crum-Cianflone MD MPH Scripps Mercy Hospital, San Diego, CA USA Abstract Background (cont.) Results Results (cont.) Background: Bacterial superinfections are well-described complications of influenza • Typically, invasive aspergillosis occurs among severely immunosuppressed hosts Case-Control Study • Systematic Review of the Literature infection, however few data exist on invasive fungal infections in this setting. The Hematologic malignancies, neutropenia, and transplant recipients 48 medical ICU patients underwent influenza testing; 8 were diagnosed with influenza N=52 and present cases (n=5) = 57 total cases • All influenza-positive patients had ventilator-dependent respiratory failure A summary of the cases is shown in Table 2 pathogenesis of invasive aspergillosis may be related to respiratory epithelium • Isolation of Aspergillus sp. in the immunocompetent host without these conditions may be initially considered as a colonizer or non-pathogen Of the 8 patients with severe influenza infection, six (75%) had Aspergillus sp. isolated Increasing number of cases over time: disruption and viral-induced lymphopenia. • 4 A. fumigatus, 1 A. fumigatus and A. versicolor, and 1 A. niger isolated • First cases described in 1979, followed by three cases in the 1980s, two cases in the 1990s, two cases in • However, recent cases have suggested that Aspergillus may rapidly lead to invasive • Since A. niger was of unknown pathogenicity this case was excluded the 2000’s, and 48 cases from 2010 to the 1st quarter of 2016 demonstrating an increasing trend of aspergillosis superinfection (p<0.001) Methods: A retrospective study was conducted among severe influenza cases requiring disease in the setting of severe influenza infection [2,3] Of the 40 patients negative for influenza admitted to the same ICU, none had Aspergillus ICU admission at a large academic hospital (2015-2016). Data collected included • Patient Characteristics Table 2: Summary of 57 Cases of Invasive Aspergillus during Influenza Infection: Current Cases and Literature Review Characteristic Number (%)* or Median (range) Aspergillus Data respiratory cultures; medical conditions; laboratory and radiographic data; and outcome. • The pathogenesis of invasive aspergillosis in this setting may include: Study population characteristics are shown in Table 1 • Of the 5 patients with Aspergillus sp. superinfection, median age was 59 years (range 47-86) Demographics Days from influenza to Aspergillus 6 (0-32)* Viral disruption of the respiratory epithelium Age, years 53 (23-86) diagnosis Aspergillosis was defined using EORTC guidelines. A systematic literature review and all were male • Local damage to the tracheobronchial mucosa and disruption of normal ciliary clearance Sex, male 38 (67%) Sites of Aspergillosis*** • None had an immunosuppressive underlying medical condition or receiving immunosuppressants prior to (PubMed; 1963-2015) of cases in the English language of aspergillosis complicating Underlying Medical Conditions at Lung 57 (100%) Impaired local immunity admission influenza was conducted. Admission Tracheobronchitis 9 (16%) • Influenza may impair local phagocytosis by alveolar macrophages as well as reduce natural • Influenza Data Vitamin“Classic underlying D deficiency disease”** has been18 (32%) increasingly recognizedSystemic among persons worldwide6 (11%) [41]. killer cell functionality and other immune responses via cytokine imbalances The influenza type was A (H1N1) (n=2) and influenza B (n=3) Underlying condition, yes 46 (81%) Species Results: Of the 48 ICU patients with influenza testing (nasopharyngeal PCR and/or Viral-induced systemic Th1/Th2 changes Types of conditions*** A. fumigatus 40 (70%) All patients received anti-influenza medications Cancer 12 (21%) A. fumigatus and A. versicolor 1 (2%) Viral-induced lymphopenia [4-8] respiratory viral culture), 8 were diagnosed with severe influenza infection. Of these, six • Aspergillus Superinfection Neutropenia 9 (16%) A. fumigatus and A. nidulans 1 (2%) (75%) had Aspergillus sp. isolated (4 A. fumigatus, 1 A. fumigatus and A. versicolor, Diabetes 9 (16%) A. niger 1 (2%) Timing between influenza and Aspergillus was a median 3 days (range 0-8) Transplantation 8 (14%) A. terreus 1 (2%) and 1 A. niger) from respiratory cultures a median of 3 days (range 0-8) after influenza All aspergillosis cases had diffuse pulmonary consolidative infiltrates Underlying lung disease 7 (12%) Not reported 13 (23%) diagnosis [3 influenza A(H1N1); 3 B]. Since A. niger was of unknown pathogenicity, this Methods • One also had fungal tracheobronchitis (Figure 1) Immunosuppressant use at admission 18 (32%) EORTC/MSG Criteria Immunosuppressed host (based on 20 (35%) Proven 21 (37%) case was excluded from the analyses. Of the 40 patients negative for influenza • Galactomannan and/or β-glucan levels were evaluated in 4 patients, and 3 (75%) condition and/or medication use) Probable 14 (25%) • Study Design: had positive results Possible 22 (39%) admitted to the same ICU, none had Aspergillus isolated. No patient with Aspergillus Influenza-Related Data Antifungal therapy, yes 53 (93%) A case-control study was conducted among patients tested for influenza infection who were admitted • Overall, case 1 met the EORTC/MSG criteria for probable aspergillosis and cases was immunosuppressed. Galactomannan and/or β-glucan levels were positive in 75% Type Outcomes to the medical ICU at a large academic hospital (400-bed) during the 2015-2016 influenza season 2-5 for possible aspergillosis A 53 (93%) of patients tested. All aspergillosis cases had diffuse pulmonary consolidative infiltrates, Mechanical ventilation Additionally, a systematic review (PubMed January 1963 - March 2016) of the English published • All cases received prompt antifungal therapy B 4 (7%) Yes 38 (67%) and all except one had lymphopenia (median 520/µl) vs. those without aspergillosis literature using the search terms “influenza” and “aspergillus” or “aspergillosis” was conducted Receipt of anti-influenza treatment 30 (53%) No 11 (19%) • Outcomes Hospitalization Data Not reported 8 (14%) (1095/µl). Mortality was 60% among influenza-Aspergillus co-infected patients, with two Mortality occurred in 3 of 5 (60%) of patients Lymphopenia (<1000 cells/μL) 19/23 (18%) ECMO 12 (21%) survivors having significant morbidity including respiratory failure >30 days. Review of • Study Population: • The two survivors had significant post-infection morbidities Steroid use, yes 18 (32%) Mortality 26 (46%) the literature and current cases yielded n=57 (EORTC: 37% proven, 25% probable, and Case control study: All ICU patients with influenza testing performed via nasopharyngeal swab *Denominator is 57 unless otherwise noted; the denominator for time to Aspergillus diagnosis was n=36. **Classic immunosuppressive condition included leukemia, neutropenia, and/or transplant recipient. All patients with an underlying condition were also on an 39% possible cases). An increasing number of cases were noted since 2010 mostly polymerase chain reaction (PCR) or respiratory viral culture immunosuppressant medication at admission, except for two patients. All patients receiving an immunosuppressant were also diagnosed with a classic • A case was defined as a patient with confirmed influenza infection who subsequently had a positive respiratory culture for Aspergillus underlying medical condition except in two cases: myasthenia gravis (n=1) and TTP (n=1) who were receiving steroids. linked to H1N1 influenza A; only 1/3 had classic underlying conditions for aspergillosis; • A control was a patient with confirmed influenza infection without evidence of Aspergillus on respiratory culture during the hospitalization ***More than one factor may be present, hence the percentage may exceed 100%. Figure 1: Fungal Tracheobronchitis Abbreviations: ECMO, extracorporeal membrane oxygenation; EORTC/MSG, European Organization for Research and Treatment of Cancer/Invasive Fungal 86% had lymphopenia; 78-88% had a positive fungal serologic markers; and overall Systematic review: Published cases of confirmed influenza as demonstrated by a positive influenza Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group; PCR, polymerase chain reaction. mortality rate was 46%. viral culture, PCR, or serology • Cases involving non-specific viral infections or without confirmatory influenza testing, reports with insufficient patient information, and Table 1: Case-Control Study of Influenza with Aspergillus Superinfection among ICU Patients, 2015-2016 instances in which the Aspergillus diagnosis preceded influenza infection were excluded Conclusions Conclusion: Aspergillosis is an emerging complication of severe influenza infections even among immunocompetent hosts. Risks may include viral-induced lymphopenia, • Study Procedures: • Aspergillus is a potential emerging complication of severe influenza infections, even although further studies are needed. Prompt diagnosis (using respiratory cultures and Data collected included respiratory cultures; medical conditions; laboratory and radiographic data; and among immunocompetent hosts outcome potentially preemptive galactomannan and/or β-glucan testing) and antifungal therapy • Progressive pulmonary infection after the initial diagnosis of influenza should raise Aspergillosis was defined using EORTC/MSG consensus guidelines [15] are recommended given
Load more

Recommended publications
  • Severe Asthma Associated with Myasthenia Gravis and Upper Airway Obstruction a Souza-Machado,1,2 E Ponte,2 ÁA Cruz2
    Severe Asthma and Myasthenia Gravis CASE REPORT Severe Asthma Associated With Myasthenia Gravis and Upper Airway Obstruction A Souza-Machado,1,2 E Ponte,2 ÁA Cruz2 1Pharmacology Department, Bahia School of Medicine and Public Health, Universidade Federal da Bahia, Salvador–Bahia, Brazil 2Asthma and Allergic Rhinitis Control Program (ProAR), Bahia Faculty of Medicine, Universidade Federal da Bahia, Salvador–Bahia, Brazil ■ Abstract An unusual association of asthma and myasthenia gravis (MG) complicated by tracheal stenosis is reported. The patient was a 35-year-old black woman with a history of severe asthma and rhinitis over 30 years. A respiratory tract infection triggered a life-threatening asthma attack whose treatment required orotracheal intubation and mechanical ventilatory support. A few weeks later, tracheal stenosis was diagnosed. Clinical manifestations of MG presented 3 years after her near-fatal asthma attack. Spirometry showed severe obstruction with no response after inhalation of 400 µg of albuterol. Baseline lung function parameters were forced vital capacity, 3.29 L (105% predicted); forced expiratory volume in 1 second (FEV1), 1.10 L (41% predicted); maximal midexpiratory fl ow rate, 0.81 L/min (26% predicted). FEV1 after administration of albuterol was 0.87 L (32% predicted). The patient’s fl ow–volume loops showed fl attened inspiratory and expiratory limbs, consistent with fi xed extrathoracic airway obstruction. Chest computed tomography scans showed severe concentric reduction of the lumen of the upper thoracic trachea. Key words: Asthma. Tracheal stenosis. Myasthenia gravis. Exacerbation. ■ Resumen En este caso informamos de una asociación infrecuente entre el asma y la miastenia grave (MG) complicada por estenosis traqueal.
    [Show full text]
  • Myasthenia Gravis
    FACT SHEET FOR PATIENTS AND FAMILIES Myasthenia Gravis What is myasthenia gravis? How is it diagnosed? Myasthenia [mahy-uh s-THEE-nee-uh] gravis is a disease Your doctor will ask you about your symptoms, where the body’s immune system attacks the perform a physical examination, and review all of connection between the nerve and muscle, causing your blood work and other tests. More blood work weakness. might be ordered to look for signs that the immune system might be attacking the muscles. A doctor may What causes it? What are the risk also perform a nerve conduction study known as factors? electromyography [ih-lek-troh-mahy-OG-ruh-fee} or EMG. Myasthenia gravis is an autoimmune [aw-toh-i-MYOON] An EMG records the electrical activity of muscles. disease. It occurs when the parts of the immune system that normally attack bacteria and viruses What are the complications? (antibodies) accidentally attack the connection If symptoms become severe, you may not be able between the nerve and muscle, also known as the to breathe normally or swallow saliva or food. This neuromuscular [noor-oh-MUHS-kyuh-ler] junction. results in aspiration [as-puh-REY-shuh n], where food or saliva goes into your airway. Serious complications The antibodies block a chemical called acetylcholine like these can result in injury or even death if left [uh-seet-l-KOH-leen], which is released by the nerve untreated. ending to activate the muscle, creating movement. Blocking this chemical causes weakness. How is it treated? Risk factors for myasthenia gravis include having a Mild symptoms are treated with a medicine called personal or family history of autoimmune diseases.
    [Show full text]
  • Multiple Sclerosis Associated with Defects in Neuromuscular Transmission
    Journal ofNeurology, Neurosurgery, and Psychiatry, 1972, 35, 385-394 J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.35.3.385 on 1 June 1972. Downloaded from Multiple sclerosis associated with defects in neuromuscular transmission BERNARD M. PATTEN, AVERY HART, AND ROBERT LOVELACE' From The Neurological Clinical Research Center, Department ofNeurology, College ofPhysicians andSurgeons, Columbia University, New York City, U.S.A. SUMMARY Three patients with multiple sclerosis characterized by exacerbations and remissions of nervous system signs and symptoms disseminated in time and space also had the kind of easy fatigu- ability seen in myasthenia gravis. In each case abnormal decrements to repetitive stimulation were electromyographically demonstrated and treatment with ephedrine or anticholinesterase drugs increased the patient's functional capacity while improving the electromyographic abnormality. The suggestion is that these patients represent an overlap syndrome, analogous to the overlap syndrome existing between systemic lupus erythematosus and rheumatoid arthritis where clinical and laboratory features of two diseases coexist in the same patient at the same time. Presumably some patients with multiple sclerosis have deficient production of acetylcholine, just like patients with myasthenia, and treatment with agents useful in myasthenia is able partially to correct the the The cases illustrate how in neurology greater attention to the symptoms caused by deficiency. Protected by copyright. more immediate cause of clinical
    [Show full text]
  • The Rare Coexistence of Systemic Lupus Erythematosus and Myasthenia Gravis in a 17-Year-Old Female
    Bahrain Medical Bulletin, Vol. 42, No. 3, September 2020 The Rare Coexistence of Systemic Lupus Erythematosus and Myasthenia Gravis in a 17-Year-Old Female Ali Alsada, BSc, MD* Basem Mustafa, MBBS, MRCP** Systemic Lupus Erythematosus (SLE) and Myasthenia Gravis (MG) are two distinct diseases, which can coexist or precede each other; however, their occurrence in the same patient is rare. This rare phenomenon has already been observed; however, only sporadic clinical cases have been described. A seventeen-year-old female who is a known case of SLE developed MG years later. Nerve conduction studies showed the decremental response over facial muscles and right median nerve. Anti-acetylcholine receptor (AChR) antibodies were positive. She was treated with oral pyridostigmine 60 mg three times a day. Clinical improvement and resolve of muscular weakness was seen within a couple of days. The patient was discharged on prednisolone 10 mg OD and pyridostigmine 60 mg TDS. Bahrain Med Bull 2020; 42 (3): 224 - 225 Systemic Lupus Erythematosus (SLE) is an autoimmune disease noticed sometimes, especially on repeated movements but there with multi-organ involvement of unknown etiology, in which was no diplopia. there is an inter-play of genetic, epigenetic and environmental factors1. It is not uncommon to find more than one autoimmune Her investigations revealed normal CBC, ESR, RFT, LFT, CK, disease in the same patient2. It has been described that SLE LDH and TSH. Thyroglobulin and smooth muscle antibodies patients can have Primary Sjogren’s Syndrome (PSS), Systemic were negative. CXR and ECG were normal. HRCT was Sclerosis (SS), Hashimoto’s Thyroiditis (HT), Myasthenia normal with no evidence of interstitial lung disease and no Gravis (MG), Polymyositis (PM) and many other autoimmune thymoma.
    [Show full text]
  • Myasthenia Gravis
    A Guide for Patients and Families What is... Myasthenia Gravis Myasthenia gravis (MG) is a chronic autoimmune MG is not inherited, and it is not contagious. Although disease — a disease that occurs when the immune MG is not hereditary, genetic susceptibility appears to system mistakenly attacks the body’s own tissues. play a role in it. Occasionally, the disease may occur in more than one member of the same family. In MG, the immune system attacks and interrupts the connection between nerve and muscle, called the MG causes weakness in muscles that control the neuromuscular junction (NMJ). This causes weakness eyes, face, neck, and limbs. Symptoms include partial in the skeletal muscles, which are responsible for paralysis of eye movements, double vision, and droopy breathing and moving parts of the body. eyelids, as well as weakness and fatigue in neck and jaws with problems in chewing, swallowing, and holding In most cases of MG, the immune system targets the up the head. acetylcholine receptor — a protein on muscle cells that is required for muscle contraction. Muscle weakness in MG gets worse with exertion and improves with rest. About 85 percent of people with MG have antibodies against the acetylcholine receptor in their blood. The Approximately 10-20 percent of people with antibodies target and destroy many of the acetylcholine MG experience at least one myasthenic crisis, an receptors on muscle. Consequently, the muscle’s emergency in which the muscles that control breathing response to repeated nerve signals declines with time, weaken to the point where the individual requires a and the muscles become weak and tired.
    [Show full text]
  • Giant Cell Arteritis Claims Are Costly and Difficult to Defend RONALD W
    Missed diagnoses: a breakdown in communication, coordination, compliance, and situational awareness THE OPHTHALMIC RISK MANAGEMENT OPHTHALMIC MUTUAL INSURANCE COMPANY VOLUME 25 NUMBER 3 2015 Giant cell arteritis claims are costly and difficult to defend RONALD W. PELTON, MD, PhD, OMIC Committee Member, and ANNE M. MENKE, RN, PhD, OMIC Risk Manager 77-year-old male patient When the patient saw the were delayed for so long and presented for the first ophthalmologist about two weeks easy to erroneously conclude that A time to our insured later, he reported a new symptom, both physicians must have been ophthalmologist to report the a low-grade fever, with ongoing incompetent. The claims investigation sudden onset of intermittent diplopia headache and diplopia. Five days showed instead that these physicians six days prior and a headache over after that—a full three weeks after the had treated patients with giant cell his eyebrows for one day. Noting initial visit to the ophthalmologist— arteritis, knew its signs and symptoms right inferior oblique muscle paresis the patient lost vision in his left well, and understood that emergent but unable to determine its cause, eye. An emergency room physician treatment is needed to prevent and with no neuro-ophthalmologist diagnosed giant cell arteritis and imminent, bilateral vision loss. What, in the region, the eye surgeon began intravenous steroid treatment, then, led these physicians astray? referred the patient to a neurologist. but the patient never regained vision Severe vision loss, costly claims The patient told the neurologist in that eye. The malpractice lawsuit that the headache had actually against the ophthalmologist settled for This issue of the Digest will report on lasted for one month and that he $85,000; we do not know the outcome a study of OMIC claims involving 18 was also experiencing jaw pain.
    [Show full text]
  • Myasthenia Associated with Other Autoimmune Diseases: a Series of Cases
    Open Journal of Internal Medicine, 2020, 10, 44-50 https://www.scirp.org/journal/ojim ISSN Online: 2162-5980 ISSN Print: 2162-5972 Myasthenia Associated with Other Autoimmune Diseases: A Series of Cases Boundia Djiba, Nafissatou Diagne, Mohamed Dieng, Baidy Sy Kane, Atoumane Faye, Awa Cheikh Ndao, Maimouna Sow, Abdoulaye Pouye Department of Internal Medicine, Aristide Ledantec Hospital, Dakar, Senegal How to cite this paper: Djiba, B., Diagne, Abstract N., Dieng, M., Kane, B.S., Faye, A., Ndao, A.C., Sow, M. and Pouye, A. (2020) Myas- We report four observations of myasthenia gravis associated with other au- thenia Associated with Other Autoimmune toimmune diseases. Myasthenia gravis can be associated with all autoimmune Diseases: A Series of Cases. Open Journal of diseases with a predominance of dysthyroidism. Among the autoimmune Internal Medicine, 10, 44-50. diseases associated with myasthenia gravis in our series, there were associa- https://doi.org/10.4236/ojim.2020.101005 tions with hyperthyroidism, sjogren syndrome, Biermer’s disease. You would Received: December 3, 2019 have to know how to look for another autoimmune disease in front of all Accepted: February 23, 2020 myasthenia gravis by looking for the slightest sign of appeal that could point Published: February 26, 2020 you towards another pathology. Copyright © 2020 by author(s) and Scientific Research Publishing Inc. Keywords This work is licensed under the Creative Myathenia Gravis, Autoimmun Disease, Association Commons Attribution International License (CC BY 4.0). http://creativecommons.org/licenses/by/4.0/ Open Access 1. Introduction Myasthenia gravis is defined as an autoimmune disease affecting the neuromus- cular junction.
    [Show full text]
  • Giant Cell Arteritis Presenting with Superior Oblique Palsy
    Giant Cell Arteritis Presenting with Superior Oblique Palsy First author: Sarah Lopez, O.D. Second author: Mariya Gurvich, O.D. Abstract An 83-year old white male presents with acute intermittent diplopia, decreased vision OD, and symptoms of headache, scalp tenderness, and jaw claudication. Examination reveals right superior oblique palsy. Temporal artery biopsy confirms giant cell arteritis. I. Case History Chief Complaint o An 83-year old white male presents with sudden decreased vision OD and diplopia. Personal Ocular History o Cataracts OU Personal Medical History o Head trauma from fall one month ago o Hypertension o Hyperlipidemia o Congestive heart failure o Abdominal aortic aneurysm o Chronic low back pain Medications o Amlodipine besylate 10 mg o Aspirin 81 mg o Atorvastatin calcium 10 mg o Furosemide 40 mg o Isoniazid 300 mg o Metoprolol succinate 100 mg o Quetiapine fumarate 50 mg o Ranitine HCL 150 mg o Valsartan 80 mg o Prednisone 100 mg II. Pertinent Findings Best-corrected Visual Acuity o OD: 20/40+ OS: 20/40 EOM's: Full OU, right hypertropia in primary gaze, improved with left head tilt Pupils: PERRL, (-) APD Slit Lamp Exam o Anterior segment: 2+ NS OU Goldmann Tonometry: o OD: 17 mmHg OS: 17 mmHg Time: 9:00 am Dilated Fundus Exam o Optic Nerve: distinct margins, pink OU . C/D: 0.25 h/v OU o Macula . Mild ERM OD, clear OS o Vessels: . Normal caliber OU, (-) emboli OU o Periphery: . No holes, tears, breaks 360 OU Laboratory Testing and Imaging o Erythrocyte sedimentation rate: 58 mm/hr (0 - 22 mm/hr) o C-reactive protein: 10.1 mg/L (<10 mg/L) o Platelet count: 393,000 cmm (150,000 - 400,000 cmm) o Fibrinogen: 632 mg/dL (200 - 400 mg/dL) o Lipid profile: Normal o Temporal artery biopsy: Positive o MRI/MRA Brain: Possible focal narrowing of both M1 segments of the middle cerebral arteries.
    [Show full text]
  • CLINICAL PRACTICE GUIDELINE Giant Cell Arteritis
    CLINICAL PRACTICE GUIDELINE CLINICAL PRACTICE GUIDELINE: Emergency Department Giant Cell Arteritis Disclaimer: This Clinical Practice Guideline (‘CPG’) was written for use in The Royal Victorian Eye and Ear Hospital Emergency Department. It should be used under the guidance of an Ophthalmology or ENT registrar. If clinical advice is required, please contact the Eye and Ear Admitting Officer for assistance: EYE: +61 3 9929 8033; ENT: +61 3 9929 8032. Links to internal Eye and Ear documents cannot be accessed from the website CPG. Description: Giant Cell Arteritis (GCA), also known as Temporal Arteritis, is a systemic vasculitis affecting medium and large arteries with significant ocular and systemic morbidity. Red Flags: • This is an ocular emergency with risk of bilateral blindness if not diagnosed and treated immediately • Patient can present with transient visual loss, diplopia or any cranial nerve palsy • Do not wait for temporal artery biopsy (TAB) before initiating steroid treatment if suspicion of GCA high • Rarely GCA is possible with a normal ESR and CRP • GCA is possible without systemic symptoms (incidence of “occult GCA” can be up to 20%) • Not every patient with an elevated ESR and/or CRP has GCA • NOTE: COVID precautions: all suspected GCA patients given high dose steroids should consider self-isolation for 2 weeks with the exception of hospital attendance for TAB or neuro-ophthalmology appointments Background: • More common in Caucasian women • Average age: 71 years old. Most patients are over 60, very rare younger than 50
    [Show full text]
  • Diseases of the Immune System 813
    Chapter 19 | Diseases of the Immune System 813 Chapter 19 Diseases of the Immune System Figure 19.1 Bee stings and other allergens can cause life-threatening, systemic allergic reactions. Sensitive individuals may need to carry an epinephrine auto-injector (e.g., EpiPen) in case of a sting. A bee-sting allergy is an example of an immune response that is harmful to the host rather than protective; epinephrine counteracts the severe drop in blood pressure that can result from the immune response. (credit right: modification of work by Carol Bleistine) Chapter Outline 19.1 Hypersensitivities 19.2 Autoimmune Disorders 19.3 Organ Transplantation and Rejection 19.4 Immunodeficiency 19.5 Cancer Immunobiology and Immunotherapy Introduction An allergic reaction is an immune response to a type of antigen called an allergen. Allergens can be found in many different items, from peanuts and insect stings to latex and some drugs. Unlike other kinds of antigens, allergens are not necessarily associated with pathogenic microbes, and many allergens provoke no immune response at all in most people. Allergic responses vary in severity. Some are mild and localized, like hay fever or hives, but others can result in systemic, life-threatening reactions. Anaphylaxis, for example, is a rapidly developing allergic reaction that can cause a dangerous drop in blood pressure and severe swelling of the throat that may close off the airway. Allergies are just one example of how the immune system—the system normally responsible for preventing disease—can actually cause or mediate disease symptoms. In this chapter, we will further explore allergies and other disorders of the immune system, including hypersensitivity reactions, autoimmune diseases, transplant rejection, and diseases associated with immunodeficiency.
    [Show full text]
  • Treatment Standards and Individualized Therapy of Myasthenia Gravis
    Review Paul Urban Peter et al. Treatment Standards and Individual- ized … Neurology International Open 2018; 00: 00–00 Treatment Standards and Individualized Therapy of Myasthenia Gravis Authors Peter Paul Urban1, Christian Jacobi2, Sebastian Jander3 Affiliations ABSTRacT 1 Neurologische Klinik, Asklepios Klinik Barmbek, Hamburg A wide range of established treatment options is currently 2 Neurologische Klinik, Krankenhaus Nordwest GmbH, available for myasthenia gravis. These include cholinesterase Frankfurt am Main inhibitors for symptomatic treatment and a broad spectrum of 3 Klinik für Neurologie, Universitätsklinikum Düsseldorf immunosuppressive, immunomodulating or cell-depleting options to modify the underlying immunological process. Ap- Key words propriate use allows the great majority of patients to lead a myasthenia gravis, neuromuscular disorder, treatment normal life. Specialized centers integrating outpatient and in-hospital resources as well as interdisciplinary competences Bibliography offer important advantages for optimum individualized therapy. DOI https://doi.org/10.1055/s-0043-124983 Neurology International Open 2018; 2: E84–E92 © Georg Thieme Verlag KG Stuttgart · New York ISSN 2511-1795 Correspondence Prof. Dr. med. Sebastian Jander, Klinik für Neurologie, Universitätsklinikum Düsseldorf, Moorenstr. 5 40225 Düsseldorf Germany [email protected] Introduction 1930s. In 1931 prostigmine (neostigmine) was first synthesized Myasthenia gravis is a well-treatable disease. Under optimal stand- and appeared to be a promising drug [2]. Lazar Remen, while work- ard therapy, approximately 85–90 % of all patients achieve good ing at the Münster University Hospital, was probably the first phy- treatment results with extensive remission of myasthenic symp- sician to treat a patient with myasthenia gravis using prostigmine, toms and recovery of everyday life skills [1].
    [Show full text]
  • GBS and MG Brochure
    MAP A TREATMENT PLAN FOR A FAST ROAD TO RESULTS Plasma Exchange for GBS and MG Patients Therapeutic Systems Unlocking the Potential of Blood PLASMA EXCHANGE: A CLEAR ROAD TO RESULTS When Quick Results Can Make a Difference for Your Patients, Consider Plasma Exchange As First-Line Therapy The Spectra Optia system is the first indicated therapeutic apheresis system to treat Guillain-Barré syndrome (GBS) and myasthenia gravis (MG) with plasma exchange. Fast results, such as response to therapy and fast recovery, can make a difference for these patients. Plasma Exchange Rapidly Reduces Disease Mediators Plasma exchange is an immunotherapeutic that rapidly reduces disease mediators and circulating immune complexes to relieve GBS and MG symptoms. Improvement following plasma exchange can occur within a few days. Physicians can quantify and measure known disease mediators before plasma exchange as well as after in order to inform the next phase of treatment providing immediate objective results.1 THE IMMUNOMODULATORY EFFECT OF PLASMA EXCHANGE2 Reduction of pathological Reduction of antibodies cytokines Reduction of immunocomplexes, Replacement of enhancing necessary plasma macrophage/monocyte components function ONE PROCEDURE CAN RAPIDLY LOWER ALL IMMUNOGLOBULINS (IgA, IgM AND IgG 1–4) UP TO % (Guptill JT, Juel VC, Massey JM, et al. Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis. Autoimmunity. 2016;49(7):472-479.) 75 DID YOU KNOW? Plasma Exchange Can Be Performed: Peripherally or by central access On an inpatient or outpatient basis GBS: IMPROVE YOUR PATIENTS’ SPEED TO RESPONSE AND RECOVERY When your GBS patients are progressing quickly, a decisive first response is critical.
    [Show full text]